AUROBINDO PHARMA LTD Q4 RESULTS
Aurobindo Pharma to commercialise China plant in third quarter of FY25: CFO
Aurobindo Pharma's China facility is set to start production in the next quarter, with full-scale output expected in the next fiscal year. The company plans to roll out small volumes in November-December, ramping up in January-March. Chief Financial Officer Santhanam Subramanian anticipates commercialisation in Q3 FY25 and volume production in FY26. The company is also progressing with Pen-G commercialization and aims for an EBITDA margin of 21-22%.
Glenmark Q1 Results: Net profit doubles to Rs 340 crore
Glenmark Pharma net profit doubled to Rs 340 crore crore in Q1FY25 led by robust sales growth in India and Europe and reduction in finance, depreciation and ammortisation costs.
Aurobindo Pharma Q1 results: Net profit jumps 61% at Rs 919 crore
Revenue from operations increased to Rs 7,567 crore in the June quarter as against Rs 6,851 crore in the year-ago period, the drug maker said in a statement.
Lupin shares surge 6%, hit 52-week high post robust Q1 result
Lupin Share Price: Lupin's shares jumped 6% to a 52-week high after the company announced a 77.2% increase in net profit for the June quarter of FY25. The firm's net profit was Rs 801.3 crore, and revenue rose 16.3% to Rs 5,600.3 crore. Nomura maintained a 'Buy' rating, forecasting continued growth.
Sun Pharma Q1 Results: Net profit rises 40% YoY to Rs 2,836 crore, beats estimates
Sun Pharma Q1 Results: Sun Pharma reported a 40% increase in consolidated net profit to Rs 2,836 crore, surpassing estimates of Rs 2,638 crore. Revenue rose 6% YoY to Rs 12,653 crore. EBITDA grew 8% YoY to Rs 3,608 crore with margins at 28.5%. India formulation sales reached Rs 4,144 crore, up 16%, constituting 33.1% of total sales.
Mankind Pharma Q1 Results: Net profit jumps 10% to Rs 543 crore
The drug maker reported net profit of Rs 494 crore in the corresponding period of previous year.Revenue from operations rose 12.2% YoY to Rs 2,893 crore in Q1FY25. On a quarter-on-quarter (QoQ) basis revenue and net profit increased 18.5% and 14%, respectively.
- Go To Page 1
Mankind Pharma Q1 Results: Profit rises 10% YoY to Rs 543 crore
Mankind Pharma Q1 Results: Revenue from operations for the same period increased by 12% year-on-year (YoY) to Rs 2,893 crore, up from Rs 2,579 crore in the previous year. The company reported an EBITDA of Rs 681 crore, reflecting a 4% YoY increase. However, margins for the quarter declined by 188 basis points to 23.54%.
Dr. Reddy's Lab Q1 Results: Profit down 1% to Rs 1,392 crore but revenue jumps 14%
Dr. Reddy's Lab Q1 Results: While announcing the quarterly numbers, the company's board also approved split of equity shares in the ratio of 1:5, which means that 1 existing share will split into 5. The company said its revenue growth during the quarter was largely driven by growth in global generics revenues in North America as well as India.
Dr Reddy's Q1 Preview: PAT may fall 4% YoY on pricing pressure, subdued US sales
In the preceding March quarter, Dr Reddy's reported a consolidated net profit growth of 36% year-on-year to Rs 1,307 crore, while revenue from operations rose 12% year-on-year to Rs 7,083 crore.
Q1 results today: IndiGo, IndusInd among 69 companies to announce earnings on Friday
Companies like Aarti Drugs, Amber Enterprises, Bandhan Bank, Cholamandalam Investment, City Union Bank, ESAF SFB, Equitas SFB, Mangalam Organics, Piramal Pharma, TTK Prestige among others will also declare their results.
Ajanta Pharma buyback: Last day today to buy shares for Rs 285 crore special situation opportunity
Ajanta Pharma has set May 30 as the record date for its Rs 285 crore share buyback,. The buyback, at a premium of 12.6%, targets 10,28,881 equity shares, constituting 8.34% of the company's aggregate equity. Amidst strong financials, the company reported a 66% YoY growth in PAT and a 20% YoY increase in revenue in its Q4 results.
Torrent Pharma, Glenmark Pharma shares jump up to 9% after Q4 results
Shares of Torrent Pharma and Glenmark Pharma surged post Q4 results. Torrent Pharma's net profit jumped 56% YoY while Glenmark Pharma reported increased losses. Motilal Oswal provides target prices for both companies.
Q4 results today: LIC, NMDC among 236 companies to announce earnings on Monday
236 companies, including LIC and NMDC, to announce Q4 results. LIC reported a 49% rise in Q3 earnings, while NMDC saw a 62% increase in consolidated net profit.
Torrent Pharma Q4 Results: Net profit jumps 56% YoY to Rs 449 crore
Torrent Pharmaceuticals Ltd on Friday reported a 56.45 per cent jump in consolidated net profit to Rs 449 crore in the March quarter, riding on higher revenue.
Torrent Pharma board approves to raise Rs 5,000 crore
Torrent Pharmaceuticals, actively seeking to expand through acquisitions, has expressed interest in purchasing Mumbai-based pharmaceutical company JB Pharma, according to a report by ET on Friday.
Glenmark Pharma Q4 Results: Net loss widens to Rs 121 crore YoY
Glenmark Pharma Q4 Results: The rise in loss was on account of declining sales in the US and exceptional items. It had reported a net loss of Rs 34.5 crore in the corresponding quarter of the previous year. In FY24, Glenmark's consolidated revenue reached Rs. 11,813 crore, a 2% increase year-over-year. The company's EBITDA margin for the fiscal year was 10.1%, primarily due to a one-time impact on sales in the India business during the third quarter.
Gland Pharma Q4 Results: Net profit more than doubles to Rs 192.4 crore
The company declared its first-ever post-listing dividend of Rs 20 per equity share for FY24.
Sun Pharma net profit jumps 34% YoY to Rs 2,654.6 crore in Q4FY24
Sun Pharma's Q4FY24 net profit rises 34% YoY to Rs 2654.6 crore, driven by increased sales of global specialty products. Interim dividend of Rs. 5 declared for FY24.
Strides Pharma Q4 Results: Pharma co reports Rs 10.4 crore net profit
Strides Pharma Science posted a net profit of Rs 10.4 crore in Q4FY24, rebounding from a loss of Rs 1 crore in the same period last year. Pre-tax profit was Rs 29.6 crore.
Sun Pharma Q4 Results: Profit jumps 34% YoY to Rs 2,654 crore, meets Street estimates
Sun Pharma Q4 Results: The company's revenue rose 10% year-on-year to Rs 11,983 crore in the reporting quarter. It was Rs 10,931 crore a year ago. Its board has approved a final dividend of Rs 5 per share, which will be paid within the prescribed timeline. India formulations sales were Rs 3,707 crore for the fourth quarter, showing growth of 10% over Q4 last year and accounted for 31.4% of total consolidated sales for the quarter.
Strides Pharma Q4 Results: Firm posts net profit of Rs 10 crore vs loss YoY
Strides Pharma Science Ltd reported a net profit of Rs 10.44 crore in Q4 ended March 2024. The company announced Arun Kumar as Executive Chairperson. Consolidated total income was Rs 1,070.49 crore with expenses at Rs 984.21 crore. A final dividend of Rs 2.50 per equity share was recommended. FY24 revenue grew driven by US and regulated markets.
Q4 results this week: ITC, ONGC, Sun Pharma, Nykaa, Ircon International and IRFC
ITC, ONGC, IRFC, Ircon International, BHEL, BEL, Sun Pharma, Nykaa, Tata Investment Corporation, Hindalco, Ashok Leyland, and Divi's lab will be releasing their March quarter report cards this week.
JB Pharma Q4 Results: Net profit jumps 43% YoY to Rs 126 crore
The Mumbai-based company reported operating earnings before interest, taxes, depreciation and amortisation (EBITDA) at Rs 210 crore, up from Rs 181 crore in the year-ago period. The operating EBITDA margin improved 60 basis points YoY to 24.4%.
Mankind Pharma Q4 Results: Net profit jumps 62% YoY to Rs 477 crore
Mankind Pharma on Wednesday reported 62% year-on-year (YoY) jump in net profit to Rs 477 crore in Q4FY24 led by strong domestic formulation sales and one-off US export opportunities.
Mankind Pharma Q4 Results: PAT zooms 62% YoY to Rs 477 crore, revenue jumps 19%
Mankind Pharma Q4 Results: The revenue from operations stood at Rs 2,441 crore versus Rs 2,053 crore reported in the year-ago period. Its board approved the raising of funds worth Rs 7,500 crore via the issuance of equity shares. For the full financial year, the consolidated PAT stood at Rs 1,942 crore as against Rs 1,310 crore reported in FY23.
Piramal Pharma shares soar 11%, hit 52-week high after Q4 profit jumps 102% YoY
The company's revenue from operations increased by 18% to Rs 2,552.4 crore as against Rs 2,163.6 crore in the corresponding period of the preceding fiscal.
Q4 results today: Tata Motors, Cipla among 87 companies to announce earnings
Q4 results today: Several other companies scheduled to release their financial results include Cholamandalam Finance, Eicher Motors, Finolex Industries, Jupiter LifeLine Hospitals, Kalyan Jewellers, Piramal Pharma, Punjab and Sind Bank, Spencers Retail, TCI Express, Thermax, and more.
Cipla Q4 Results Preview: Profit may rise up to 71% YoY on healthy operations
Cipla Q4 Results Preview: As per the combined projections of four brokerages, there's a possibility of the net profit for the fourth quarter surging by as much as 71% year-on-year, alongside an expected 7% year-on-year increase in net sales.
Q4 results today: PB Fintech, Dr Reddy's among 43 companies to announce results
Q4 results today: 43 companies are set to announce Q4 results, with Dr Reddy's and PB Fintech in focus. Dr Reddy's eyes revenue and net profit growth, while PB Fintech anticipates 18% YoY growth in core business premium.
Load More
